Drugs Health Pharma

GSK’s vaccine for severe RSV shows 43.3% effectiveness in third year

GSK Plc.’s single dose respiratory syncytial virus (RSV) vaccine for a severe form of the disease proved 43.3% effective in the third season.

Read More
Drugs Health Pharma

EC approves Merck’s bladder cancer combination therapy in adults 

Merck & Co., got approval from the European Commission to market its combination therapy to treat metastatic urothelial cancer or bladder cancer in.

Read More
Drugs Medical Pharma

Basilea Pharmaceutica to get $1.25m license fee from Pfizer

Switzerland’s Basilea Pharmaceutica Ltd. will receive $1.25 million from its partner Pfizer Inc. after the latter exceeded the sales target for a licensed.

Read More
Drugs Health Pharma

‘Strong neutralizing responses’ shown in RSV vaccine trials: Pfizer says

Pfizer Inc.’s vaccine trials on patients aged 18 and older with chronic respiratory diseases show a consistent safety profile and “strong neutralizing responses,”.

Read More
Drugs Health Pharma

Pfizer’s haemophilia A gene therapy cuts bleeding rates during trials

HQ Team July 25, 2024: Pfizer’s haemophilia A gene therapy has reduced bleeding rates in patients during an end-stage trial, according to a.

Read More
Drugs Health Pharma

Pfizer, BioNTech gets EMA marketing nod for variant Covid-19 vaccine

The European Medicines Agency has allowed marketing authorisation for the Covid-19 variant vaccine made by Pfizer and BioNTech SE for children aged six.

Read More
Drugs Health Pharma

Pfizer’s blood cancer trial data shows survival of more than 2 years 

Pfizer Inc.,’s investigational drug for blood cancer, Elrexfio, has shown an overall survival rate of 24.6 months in a single-arm trial, according to.

Read More
Drugs Health Pharma

Pfizer’s Duchenne muscular dystrophy trial fails to meet primary goal

Pfizer’s investigations on gene therapy for patients with Duchenne muscular dystrophy failed to meet its primary goals, according to a company statement.

Read More
Drugs Health Pharma

Pfizer’s drug helps people with rare lung cancer live longer, data shows

Sixty percent of the patients treated with Pfizer’s Lorbrena drug, for a rare form of advanced lung cancer, were alive without disease progression.

Read More
Drugs Health Pharma

Pfizer Inc. unveils a new $1.5 billion plan to cut costs as vaccine sales fall

Pfizer Inc., announced a $1.5 billion “multi-year” savings plan to cut costs of goods sold, on top of a similar $4 billion initiative.

Read More
X